Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| DRKS00005263 | Registry Identifier | Deutsches Register Klinischer Studien |
Not provided
Not provided
Sponsor is bankrupt
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of the PHSTT-01 trial is to determine if prostate HistoScanning (HS) analysis can be used to improve the detection of clinically significant prostate cancer (PCa), and potentially reduce the burden and number of biopsies in routine clinical practice. Prostate HS is an ultrasound-based tissue characterization technology specifically developed to detect, visualize, and locate tissue suspected of harboring PCa. These suspicious tissues are displayed as red areas on an imaging monitor. Recently a new biopsy guidance tool has been developed that uses the results of the prostate HS analysis.
The subjects that will participate in this study are all scheduled for a first biopsy of the prostate. They will initially be imaged using transrectal ultrasound (TRUS) to obtain data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo a routine systematic 10- to 12-core biopsy procedure using TRUS. This will be followed by a TRUS-guided biopsy that uses the result of prostate HS analysis and new biopsy guidance tool.
PHSTT-01 is a multi-center, prospective clinical trial to evaluate the diagnostic performance of prostate HistoScanning (HS) analysis in men at risk of PCa that have been scheduled for a first prostate biopsy. The purpose of this study is to determine if prostate HS analysis can improve the detection of clinically significant PCa, and potentially reduce the burden and number of biopsies in routine clinical practice. Subjects are men with serum total prostate-specific antigen (PCA) <= 20ng/mL (<= 10ng/mL if taking the 5-alpha reductase inhibitor).
In a single visit, subjects will first be imaged with TRUS for the purpose of generating data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero to a maximum of 6 cores.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| single arm study | Other | Prostate HistoScanning (HS) analysis with HS-guided biopsy will be used to sample two cores per suspicious area (displayed as red on an imaging monitor), up to a maximum of 3 suspicious areas per subject. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero (if no suspicious area is identified) up to a maximum of 6 cores. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Prostate HistoScanning | Device | In a single visit, subjects will first be imaged with TRUS for the purpose of generating data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero to a maximum of 6 cores. |
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic performance of prostate HistoScanning (HS) to identify clinically significant PCa using histology outcomes from systematic prostate biopsy (Bx) as reference | Compare prostate HS results to the systematic Bx outcome (positive or negative) for clinically significant PCa (defined as Gleason sum ≥ 7) in the non-run-in population. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic performance of prostate HS to identify PCa using histology outcomes from systematic Bx as reference | Compare prostate HS results to the systematic Bx outcome (positive or negative) for all PCa in the non-run-in population. | 1 year |
| Diagnostic performance of prostate HS to identify clinically significant PCa using a combination of outcomes of both systematic Bx and HS-guided biopsy histology as reference |
Not provided
Inclusion Criteria:
Men at risk of PCa scheduled for first biopsy with serum total PSA
≤ 20 ng/ml (≤ 10 ng/mL if taking 5-alpha reductase inhibitors) from maximally 3 months ago
Signed informed consent
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bertrand Tombal, Prof | Cliniques Universitaires Saint-Luc, Brussels, Belgium | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Krankenhaus der Barmherzigen Brüder | Vienna | 1020 | Austria | |||
| Medical Center Hanuschkrankenhaus |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
Compare prostate HS results to the combination of systematic and HS-guided Bx outcomes (positive or negative) for clinically significant PCa (defined as Gleason sum ≥ 7) in the non-run-in population. |
| 1 year |
| Difference in detection rates of clinically significant PCa between systematic and HS-guided biopsy. | Compared PCa detection rates of systematic and HS-guided prostate Bx in the non-run-in population. | 1 year |
| Vienna |
| 1140 |
| Austria |
| Medical Center Med.Landeskrankenhaus Vöcklabruck | Vöcklabruck | 4840 | Austria |
| University Medical Center UZ VUB | Brussels | Brussels Capital | 1090 | Belgium |
| • University Medical Center Cliniques Universitaires Saint Luc | Brussels | Brussels Capital | 1200 | Belgium |
| Medical Center Onze Lieve Vrouw Ziekenhuis OLVZ | Aalst | 9300 | Belgium |
| University Medical Center St. Marina University Hospital | Varna | 9010 | Bulgaria |
| Medical Center Urologická klinika - Fakultní nemocnice | Olomouc | 775 20 | Czechia |
| University Medical Center Všeobecná fakultní nemocnice v Praze (VFN) a 1. -General University Hospital and First Faculty of Medicine Charles University | Prague | 15006 | Czechia |
| • University Medical Center Urinary Tract Surgery - Urology Dpt - Odense Universitetshospital Svendborg Sygehus | Odense C | 5000 | Denmark |
| Medical Center North-Estonian Medical Center Foundation | Tallinn | 13419 | Estonia |
| Medical Center Institut Mutualiste Montouris | Paris | 75014 | France |
| University Medical Center CHU Saint Etienne | Saint-Etienne | 42055 | France |
| Medical Center Cancer Center - Prostatazentrum | Braunschweig | 38126 | Germany |
| Medical Center PAN Klinik | Cologne | 50667 | Germany |
| Medical Center Paracelsus Klinik | Düsseldorf | 40474 | Germany |
| Medical Center Martini Klinik - Prostate Cancer Center | Hamburg | 20246 | Germany |
| Medical Center Klinikum Herford | Herford | 32049 | Germany |
| Medical Center St. Elisabeth Krankenhaus | Leipzig | 04277 | Germany |
| Medical Center Klinikum Leverkusen | Leverkusen | 51375 | Germany |
| Medical Center Klinikum Wolfsburg Urologie | Wolfsburg | 38440 | Germany |
| Medical Center Uro-Clin Ltd | Pécs | 7601 Pf. 246 | Hungary |
| University Medical Center University Vita-Salute, Scientific Institute H. San Raffaele | Milan | 20132 | Italy |
| Medical Center URO | Riga | 1006 | Latvia |
| University Medical Center Vilniaus Universiteto Onkologijos Institutas - Santariškiu Clinics | Vilnius | 08406 | Lithuania |
| Medical Center Antoni Van Leeuwenhoek Ziekenhuis - Nederlands Kanker Instituut | Amsterdam | 1066 CX | Netherlands |
| University Medical Center Moscow State University of Medicine and Dentistry named after A.I.Evdokimov | Moscow | 127473 | Russia |
| University Medical Center Vall d'Hebron University Hospital - Autonoma Universitat Barcelona | Barcelona | 08035 | Spain |
| Carouge medical centre | Carouge | 1227 | Switzerland |
| Medical Center URO-TIP Urological Diagnosis Center | Istanbul | 34740 | Turkey (Türkiye) |
| Medical Center Acıbadem Kozyatağı Hospital | Istanbul | 34742 | Turkey (Türkiye) |
| Medical Center Blackpool Victoria Hospital | Blackpool | FY38NR | United Kingdom |
| University Medical Center Nuffield Health - University Hospitals Bristol (UHB) - Bristol Royal Infirmary and Southmead Hospitals | Bristol | BS28HW | United Kingdom |
| Medical Center Spire Washington Hospital | Tyne and Wear | NE38 9JZ | United Kingdom |
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided